| Guillain-Barré syndrome related to COVID-19 infection P Alberti, S Beretta, M Piatti, A Karantzoulis, ML Piatti, P Santoro, ... Neurology: Neuroimmunology & Neuroinflammation 7 (4), e741, 2020 | 441 | 2020 |
| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, B Frigeni, ... Annals of Oncology 24 (2), 454-462, 2013 | 368 | 2013 |
| Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools G Cavaletti, B Frigeni, F Lanzani, L Mattavelli, E Susani, P Alberti, ... European journal of cancer 46 (3), 479-494, 2010 | 330 | 2010 |
| Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer AA Argyriou, G Cavaletti, C Briani, R Velasco, J Bruna, M Campagnolo, ... Cancer 119 (2), 438-444, 2013 | 270 | 2013 |
| Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire M Van Leeuwen, O Husson, P Alberti, JI Arraras, OL Chinot, A Costantini, ... Health and quality of life outcomes 16, 1-15, 2018 | 259 | 2018 |
| Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin P Alberti, E Rossi, DR Cornblath, ISJ Merkies, TJ Postma, B Frigeni, ... Annals of oncology 25 (1), 257-264, 2014 | 192 | 2014 |
| Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients R Velasco, J Bruna, C Briani, AA Argyriou, G Cavaletti, P Alberti, B Frigeni, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (4), 392-398, 2014 | 173 | 2014 |
| Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics G Cavaletti, P Alberti, P Marmiroli The lancet oncology 12 (12), 1151-1161, 2011 | 150 | 2011 |
| Voltage‐gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin‐induced peripheral neurotoxicity: Results from a prospective multicenter study AA Argyriou, G Cavaletti, A Antonacopoulou, AA Genazzani, C Briani, ... Cancer 119 (19), 3570-3577, 2013 | 139 | 2013 |
| Chemotherapy-induced neuropathy G Cavaletti, P Alberti, B Frigeni, M Piatti, E Susani Current treatment options in neurology 13, 180-190, 2011 | 137 | 2011 |
| Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients AA Argyriou, R Velasco, C Briani, G Cavaletti, J Bruna, P Alberti, ... Annals of oncology 23 (12), 3116-3122, 2012 | 125 | 2012 |
| Efficacy of a novel sigma-1 receptor antagonist for oxaliplatin-induced neuropathy: a randomized, double-blind, placebo-controlled phase IIa clinical trial J Bruna, S Videla, AA Argyriou, R Velasco, J Villoria, C Santos, C Nadal, ... Neurotherapeutics 15 (1), 178-189, 2018 | 117 | 2018 |
| Long‐term course of oxaliplatin‐induced polyneuropathy: a prospective 2‐year follow‐up study C Briani, AA Argyriou, C Izquierdo, R Velasco, M Campagnolo, P Alberti, ... Journal of the Peripheral Nervous System 19 (4), 299-306, 2014 | 113 | 2014 |
| Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings AA Argyriou, SB Park, B Islam, S Tamburin, R Velasco, P Alberti, J Bruna, ... Journal of Neurology, Neurosurgery & Psychiatry 90 (12), 1361-1369, 2019 | 100 | 2019 |
| Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue G Cavaletti, P Alberti, AA Argyriou, M Lustberg, NP Staff, S Tamburin, ... Journal of the Peripheral Nervous System 24, S6-S12, 2019 | 85 | 2019 |
| Chemotherapy‐induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale B Frigeni, M Piatti, F Lanzani, P Alberti, P Villa, C Zanna, M Ceracchi, ... Journal of the peripheral nervous system 16 (3), 228-236, 2011 | 85 | 2011 |
| Overview and critical revision of clinical assessment tools in chemotherapy‐induced peripheral neurotoxicity SB Park, P Alberti, NA Kolb, JS Gewandter, A Schenone, AA Argyriou Journal of the Peripheral Nervous System 24, S13-S25, 2019 | 83 | 2019 |
| Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy C Meregalli, G Fumagalli, P Alberti, A Canta, VA Carozzi, A Chiorazzi, ... Experimental neurology 307, 129-132, 2018 | 77 | 2018 |
| Bortezomib and other proteosome inhibitors—induced peripheral neurotoxicity: From pathogenesis to treatment R Velasco, P Alberti, J Bruna, D Psimaras, AA Argyriou Journal of the Peripheral Nervous System 24, S52-S62, 2019 | 76 | 2019 |
| OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity AF Leblanc, JA Sprowl, P Alberti, A Chiorazzi, WD Arnold, AA Gibson, ... The Journal of clinical investigation 128 (2), 816-825, 2018 | 73 | 2018 |
guido cavalettiuniversità di Milano BicoccaPatvirtintas el. paštas unimib.it
